TOP STORIES
haematology

ISTH 2019

Saturday 6th - Wednesday 10th July 2019
Research

Novel anti-platelet agent engineered by Australian researchers

Australian and US researchers have genetically engineered a novel antithrombotic drug, which binds only to activated platelets at the site of a thrombus. By only binding to activated platelets, not sealing platelets, there is no risk of bleeding complications with the...

Australian and US researchers have genetically engineered a novel antithrombotic drug, which binds only to activated platelets at the site...
Coagulation

Breakthrough therapy for haemophilia B

The rebalancing agent concizumab has the potential to fulfil a need for new treatment options across all haemophilia subtypes but importantly for patients with haemophilia B and inhibitors. Speaking at the ISTH Congress, Associate Professor Jan Astermark said that the US...

The rebalancing agent concizumab has the potential to fulfil a need for new treatment options across all haemophilia subtypes but...
Coagulation

The rise of the machines in DVT?

Machine learning is either the future of medicine or a distraction from clinical medicine - if the lively discussion at ISTH Congress is anything to go by. The discussion was generated after Dr John Willan, from Oxford University Hospitals, told the...

Machine learning is either the future of medicine or a distraction from clinical medicine - if the lively discussion at...